KohlmannRSalmenAChanAet al. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Mult Scler2015; 21: 1823–1832.
2.
RothhammerVMuschaweckhAGasteigerGet al. α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol Commun2014; 2: 27.
3.
PerkinsMRRyschkewitschCLiebnerJCet al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog2012; 8: e1003014.
4.
Ben FredjNRizzoRBortolottiDet al. Evaluation of the implication of KIR2DL2 receptor in multiple sclerosis and herpesvirus susceptibility. J Neuroimmunol2014; 271: 30–35.
5.
MuleroPAugerCParolinLet al. Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab. Mult Scler2018; 24: 358–360.
6.
BerlinJAGlasserSCEllenbergSS.Adverse event detection in drug development: Recommendations and obligations beyond phase 3. Am J Public Health2008; 98: 1366–1371.
7.
McGuiganCCranerMGuadagnoJet al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosurg Psychiatry2016; 87: 117–125.
8.
SalmenAGoldRChanA.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clin Exp Immunol2014; 176: 135–148.
